Michael acceptor containing drugs are a novel class of 5-lipoxygenase inhibitor targeting the surface cysteines C416 and C418
![Vista Previa No Disponible](/themes/Mirage2//images/vdspace.png)
Autor
Piesche, Matthias
Maucher, Isabelle V.
Rühl, Michael
Kretschmer, Simon B.M.
Hofmann, Bettina
Kühn, Benjamin
Fettel, Jasmin
Vogel, Anja
Flügel, Karsten T.
Manolikakes, Georg
Hellmuth, Nadine
Häfner, Ann-Kathrin
Golghalyani, Vahid
Ball, Ann-Katrin
Matrone, Carmela
Geisslinger, Gerd
Parnham, Michael J.
Karas, Michael
Steinhilber, Dieter
Roos, Jessica
Maier, Thorsten J.
Fecha
2017Resumen
Recently, we published that nitro-fatty acids (NFA) are potent electrophilic molecules which inhibit 5-lipoxygenase (5-LO) by interacting catalytically with cysteine residues next to a substrate entry channel. The electrophilicity is derived from an intramolecular Michael acceptor moiety consisting of an electron-withdrawing group in close proximity to a double bond. The potential of the Michael acceptor moiety to interact with functionally relevant cysteines of proteins potentially renders them effective and sustained enzyme activity modulators. We screened a large library of naturally derived and synthetic electrophilic compounds to investigate whether other types of Michael acceptor containing drugs suppress 5-LO enzyme activity. The activity was measured by assessing the effect on the 5-LO product formation of intact human polymorphonuclear leukocytes. We demonstrated that a number of structurally different compounds were suppressive in the activity assays and showed that Michael acceptors of the quinone and nitro-alkene group produced the strongest inhibition of 5-LO product formation. Reactivity with the catalytically relevant cysteines 416 and 418 was confirmed using mutated recombinant 5-LO and mass spectrometric analysis (MALDI-MS). In the present study, we show for the first time that a number of well-recognized naturally occurring or synthetic anti-inflammatory compounds carrying a Michael acceptor, such as thymoquinone (TQ), the paracetamol metabolite NAPQI, the 5-LO inhibitor AA-861, and bardoxolone methyl (also known as RTA 402 or CDDO-methyl ester) are direct covalent 5-LO enzyme inhibitors that target the catalytically relevant cysteines 416 and 418.
Fuente
Biochemical Pharmacology, 125, 55-74Link de Acceso
Click aquí para ver el documentoIdentificador DOI
doi.org/10.1016/j.bcp.2016.11.004Colecciones
La publicación tiene asociados los siguientes ficheros de licencia: